nach oben

Die Onkologie

Erschienen in:

28.04.2019 | Zervixkarzinom | CME

Radiochemotherapie des Zervixkarzinoms

verfasst von: Prof. Dr. med. S. Marnitz, J. Morgenthaler, S. Kunze, J. Herter

Erschienen in: Die Onkologie | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die primäre kombinierte Radiochemotherapie ist Standard beim lokal fortgeschrittenen und nodal positivem Zervixkarzinom. Eine Kombination aus radikaler Hysterektomie und Radiochemotherapie sollte vermieden werden. Bei histologisch gesicherten Lymphknotenmetastasen paraaortal wird mit EFRT („extended field radiation therapy“) eine exzellente lokale Kontrolle erzielt, die Hälfte der Betroffenen erreicht ein Langzeitüberleben. Die neoadjuvante Chemotherapie gefolgt von Hysterektomie sollte nur im Rahmen von Studien erfolgen. Bei Metastasierung, progredienter Erkrankung oder lokal fortgeschrittenen, nicht operativ sanierbaren Befunden stellt die Kombination von Bevacizumab mit Paclitaxel/Cisplatin oder Paclitaxel/Topotecan den derzeitigen Standard dar. Als immunogener Tumor ist das Zervixkarzinom auch ein gutes Ziel für Immuntherapeutika.

Bhatla N et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. https://doi.org/10.1002/ijgo.12749 CrossRefPubMed

Alberts DS, Brady M, Cikaric S, Chen HW, Dinshaw K, Eifel PJ, Garipagaoglu M, Jakobsen A, Kantardzic N, Keys H et al (2010) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd008285 CrossRef

Nagy VM, Ordeanu C, Coza O, Alin CR, Traila A, Todor N (2012) Randomized phase 3 trial comparing 2 cisplatin dose schedules in 326 patients with locally advanced squamous cell cervical carcinoma: long-term follow-up. Int J Gynecol Cancer 22:1538–1544PubMed

Lin JF, Berger JL, Krivak TC, Beriwal S, Chan JK, Sukumvanich P, Monk BJ, Richard SD (2014) Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 132:416–422CrossRef

Mazeron R, Castelnau-Marchand P, Dumas I, del Campo ER, Kom LK, Martinetti F, Farha G, Tailleur A, Morice P, Chargari C et al (2015) Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol 114:257–263CrossRef

Shaverdian N, Gondi V, Sklenar KL, Dunn EF, Petereit DG, Straub MR, Bradley KA (2013) Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 86:562–568CrossRef

Showalter TN, Camacho F, Cantrell LA, Anderson RT (2016) Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. Medicine (Baltimore) 95:e2913CrossRef

Ghadjar P, Budach V, Kohler C, Jantke A, Marnitz S (2015) Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. Radiat Oncol 10:50CrossRef

Smith GL, Jiang J, Giordano SH, Meyer LA, Eifel PJ (2015) Trends in the Quality of Treatment for Patients With Intact Cervical Cancer in the United States, 1999 Through 2011. Int J Radiat Oncol Biol Phys 92:260–267CrossRef

10.

Atri M, Zhang Z, Dehdashti F, Lee SI, Ali S, Marques H, Koh WJ, Moore K, Landrum L, Kim JW et al (2016) Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol 142:413–419CrossRef

11.

Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117:1928–1934CrossRef

12.

Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, Querleu D, Haie-Meder C, Leblanc E (2012) Nodal-staging surgery for locally advanced cervical cancer in the era of PET. Lancet Oncol 13:E212–E220CrossRef

13.

Tsunoda AT, Marnitz S, Soares Nunes J, Mattos de Cunha Andrade CE, Scapulatempo Neto C, Blohmer JU, Herrmann J, Kerr LM, Martus P, Schneider A et al (2017) Incidence of Histologically proven pelvic and para-aortic lymph node metastases and rate of upstaging in patients with locally advanced cervical cancer: results of a prospective randomized trial. Oncology 92:213–220CrossRef

14.

Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, LeBlanc E, Martinez A, Ramirez PT (2014) Lymphadenectomy in locally advanced cervical cancer study (LiLACS): phase III clinical trial comparing surgical with radio logic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol 21:3–8CrossRef

15.

Yan K, Ramirez E, Xie XJ, Gu X, Xi Y, Albuquerque K (2018) Predicting severe hematologic toxicity from extended-field chemoradiation of para-aortic nodal metastases from cervical cancer. Pract Radiat Oncol 8:13–19CrossRef

16.

Azais H, Ghesquiere L, Petitnicolas C, Borghesi Y, Tresch-Bruneel E, Cordoba A, Narducci F, Bresson L, Leblanc E (2017) Pretherapeutic staging of locally advanced cervical cancer: Inframesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy. Gynecol Oncol 147:340–344CrossRef

17.

Chantalat E, Vidal F, Leguevaque P, Lepage B, Mathevet P, Deslandres M, Motton S (2015) Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers. Eur J Obstet Gynecol Reprod Biol 193:118–122CrossRef

18.

Marnitz S, Schram J, Budach V, Sackerer I, Vercellino GF, Sehouli J, Kohler C (2015) Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy. Strahlenther Onkol 191:421–428CrossRef

19.

Yoon HI, Cha J, Keum KC, Lee HY, Nam EJ, Kim SW, Kim S, Kim YT, Kim GE, Kim YB (2015) Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis. Radiat Oncol 10:18. https://doi.org/10.1186/s13014-014-0320-5 CrossRefPubMedPubMedCentral

20.

Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW, Cooper J, John M (1995) Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 274:387–393CrossRef

21.

Haie C, Pejovic MH, Gerbaulet A, Horiot JC, Pourquier H, Delouche J, Heinz JF, Brune D, Fenton J, Pizzi G et al (1988) Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 11:101–112CrossRef

22.

Wang W, Liu X, Meng Q, Zhang F, Hu K (2018) Prophylactic extended-field irradiation for patients with cervical cancer treated with concurrent chemoradiotherapy: a propensity-score matching analysis. Int J Gynecol Cancer 28(8):1584–1591. https://doi.org/10.1097/IGC.0000000000001344.CrossRefPubMedPubMedCentral

23.

Manders DB, Sims TT, Bailey A, Hwang L, Richardson DL, Miller DS, Kehoe SM, Albuquerque KV, Lea JS (2018) The significance of para-aortic nodal size and the role of Adjuvant systemic chemotherapy in cervical cancer: an institutional experience. Am J Clin Oncol 41(12):1225–1230. https://doi.org/10.1097/COC.0000000000000458 CrossRefPubMed

24.

Oh J, Seol KH, Lee HJ, Choi YS, Park JY, Bae JY (2017) Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer. Radiat Oncol J 35:349–358CrossRef

25.

Lee J, Lin JB, Chang CL, Jan YT, Sun FJ, Wu MH, Chen YJ (2017) Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience. Gynecol Oncol 146:20–26CrossRef

26.

Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C (1997) Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet 350:535–540CrossRef

27.

Marnitz S, Kohler C, Affonso RJ, Schneider A, Chiantera V, Tsounoda A, Vercellino F (2012) Validity of laparoscopic staging to avoid adjuvant chemoradiation following radical surgery in patients with early cervical cancer. Oncology 83:346–353CrossRef

28.

Yagur Y, Weitzner O, Gemer O, Lavie O, Beller U, Bruchim I, Vaknin Z, Levy T, Rabinovich A, Shachar IB et al (2018) Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group Study. Gynecol Oncol 150:288–292CrossRef

29.

Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J et al (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1548–1555. https://doi.org/10.1200/JCO.2017.75.9985 CrossRefPubMed

30.

Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20:179–188CrossRef

31.

Benedetti Panici P, Palaia I, Marchetti C, Ruscito I, Fischetti M, Musella A, Di Donato V, Perniola G, Vertechy L, Muzii L (2015) Dose-dense Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer: a phase II study. Oncology 89:103–110CrossRef

32.

Landoni F, Sartori E, Maggino T, Zola P, Zanagnolo V, Cosio S, Ferrari F, Piovano E, Gadducci A (2014) Is there a role for postoperative treatment in patients with stage Ib(2)–IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol Oncol 132:611–617CrossRef

33.

Marnitz S, Martus P, Köhler C, Stromberger C, Asse E, Mallmann P, Schmidberger C, Júnior ARJ, Nunes JS, Sehouli J (2016) Role of surgical versus clinical staging in chemoradiated FIGO stage IIB–IVA cervical cancer patients—acute toxicity and treatment quality of the uterus-11 Multicenter phase III intergroup trial of the German radiation oncology group and the gynecologic cancer group. Int J Radiat Oncol Biol Phys 94:243–253CrossRef

34.

Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743CrossRef

35.

Hollebecque A, Meyer T, Moore KN, Machiels JPH, De Greve J, Lopez-Picazo JM, Oaknin A, Kerger JN, Boni V, Evans TRJ et al (2017) An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 35. https://doi.org/10.1200/jco.2017.35.15_suppl.5504 CrossRef

36.

Schellens JHM, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC (2017) Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol 35. https://doi.org/10.1200/jco.2017.35.15_suppl.5514 CrossRefPubMedPubMedCentral

37.

Minion LE, Tewari KS (2018) Cervical cancer—State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 148:609–621CrossRef

38.

Papadopoulos KP, Crittenden MR, Johnson ML, Lockhart AC, Moore KN, Falchook GS, Formenti S, Carvajal RD, Leidner RS, Naing A et al (2016) A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT). J Clin Oncol 34. https://doi.org/10.1200/jco.2016.34.15_suppl.3024 CrossRefPubMedPubMedCentral

39.

Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280CrossRef

40.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2‑year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558–1568CrossRef

41.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbe C, Kirkwood JM, Schachter J, Daniels GA et al (2017) Pooled analysis safety profile of Nivolumab and Ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35:3815–3822CrossRef

42.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H et al (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100:916–925CrossRef

Titel: Radiochemotherapie des Zervixkarzinoms
verfasst von: Prof. Dr. med. S. Marnitz
J. Morgenthaler
S. Kunze
J. Herter
Publikationsdatum: 28.04.2019
Verlag: Springer Medizin
Schlagwörter: Zervixkarzinom
Zytostatische Therapie
Metastasen
Zervixkarzinom
Hysterektomie
Bevacizumab
Erschienen in: Die Onkologie / Ausgabe 6/2019
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-019-0575-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Radiochemotherapie des Zervixkarzinoms

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Algorithmus Nierenzellkarzinom: Was wann zu tun ist

Bildgebung bei Nierenzellkarzinom

Epidemiologie des Nierenzellkarzinoms in Deutschland

Familienorientierte Kunsttherapie für Kinder und Jugendliche mit Krebs sowie deren Eltern im Akutkrankenhaus

Pathologie und Molekularpathologie des Nierenzellkarzinoms

Neue Therapieansätze beim metastasierten Nierenzellkarzinom

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie